(found: C, 67.08; H, 7.44); and also was oxidized with chromium trioxide in pyridine to 9α -fluoro- 17α -acetoxy-4-pregnene-3,11,20-trione (IX); m.p. $256-258^{\circ}$; $[\alpha]_{\rm D}$ +112° (CHCl₃); $\lambda_{\rm max.}^{\rm methanol}$ 235 m μ , ϵ = 16,990; (found: C, 68.62; H, 7.07).

When tested orally in the Clauberg assay⁸ at a level producing a +2 degree of glandular arborization the compounds had these relative potencies (subcutaneous progesterone = 1); V = 5; VII = 25; VIII = 10; IX = 10. In our hands compound VII is 2500 times as potent as progesterone is orally, 25 times as potent as Norlutin, and 5 times as potent as 6α -methyl- 17α -acetoxyprogesterone ⁹

(8) C. W. Emmens, "Hormone Assay," Academic Press, Inc., New York, N. Y., 1950, p. 422.

(9) J. C. Babcock, E. S. Gutsell, M. E. Herr, J. A. Hogg, J. C. Stucki, L. E. Barnes and W. E. Dulin, This Journal, 80, 2904 (1958).

G. D. SEARLE AND COMPANY P. O. Box 5110 CHICAGO 80, ILLINOIS CLARENCE G. BERGSTROM ROBERT T. NICHOLSON R. L. ELTON R. M. DODSON

RECEIVED JUNE 15, 1959

A NOVEL RESOLUTION OF 1-PHENYL-2-PROPYLHYDRAZINE

Sir:

In view of the recent paper by Biel and coworkers1 on the chemistry and structure-activity relationships of aralkyl hydrazines as central stimulants and the current interest in several of these compounds as possible therapeutic agents,2 we wish to report at this time a unique resolution of 1-phenyl-2-propylhydrazine by means of its L-pyroglutamoyl derivative. L-Pyroglutamic hydrazide, $[\alpha]^{25}D - 10.1$ (c, 1.0 in water) was condensed with 1-phenyl-2-propanone to yield N-L-pyroglutamoyl-N'-(1-phenyl-2-propylidene)-hydrazine, m.p. $152-154^{\circ}$, $[\alpha]^{27}_{D} + 17^{\circ}$ (c, 1.0 in ethanol). Anal. Calcd. for $C_{14}H_{17}N_3O_2$: C, 64.84; H, 6.61. Found: C, 65.07; H, 6.39. Reduction of this hydrazide with sodium borohydride in aqueous methanol yielded a mixture of isomers which were separated by fractional crystallization from water or acetonitrile. The higher-melting insoluble isomer (A) melted at $163-\overline{1}64^{\circ}$, $[\alpha]^{25}\overline{D}$ +24.4 (c, 1.0 in water). Anal. Calcd. for $C_{14}H_{19}$ -N₃O₂: C, 64.34; H, 7.32; N, 16.08. Found: C, 64.39; H, 7.20; N, 16.01. The lower-melting soluble isomer (B) melted at 83–86°, $[\alpha]^{24}_{\rm D}$ – 14.6° (c, 1.0 in water). Anal. Found: C, 64.31; H, 7.34; N, 15.96. Hydrolysis of (A) in aqueous hydrochloric acid gave p-1-phenyl-2-propylhydrazine hydrochloride, m.p. $148-149^{\circ}$, $[\alpha]^{25}_{\rm D}+13.8^{\circ}$ (c, 1.0 in water). Anal. Calcd. for C_9H_{15} -ClN₂: Cl, 18.99; N, 15.00. Found: Cl, 18.70; N, 14.81. Hydrolysis of (B) under similar conditions gave L-1-phenyl-2-propylhydrazine hydrochloride, m.p. 148–149°, $[\alpha]^{25}$ D -14.0° (c, 1.0) in water).

To establish the configuration of the isomers relative to D-amphetamine, the D-isomer was re-

duced with palladium-on-charcoal as the catalyst. The amine thus obtained was benzoylated to yield D - N - (1 - phenyl - 2 - propyl) - benzamide, m.p. $155-156^{\circ}$, $[\alpha]^{25}_{\rm D}+71.6^{\circ}$ (c, 1.1 in methanol). Anal. Calcd. for $\rm C_{16}H_{17}NO$. N, 5.85. Found: N, 6.05. A sample of D-amphetamine also was benzoylated to yield an authentic sample of D-N-(1-phenyl-2-propyl)-benzamide, m.p. $155-156^{\circ}$, $[\alpha]^{25}_{\rm D}+72^{\circ}$ (c, 1.0 in methanol). A mixture m.p. showed no depression. A similar reduction of the L-isomer with subsequent benzoylation yielded L-N-(1-phenyl-2-propyl)-benzamide, m.p. $155-156^{\circ}$, $[\alpha]^{25}_{\rm D}-71.3^{\circ}$ (c, 0.97 in methanol). A mixture m.p. with D-N-(1-phenyl-2-propyl)-benzamide was $130-131^{\circ}$.

Preliminary pharmacological tests indicate that D-1-phenyl-2-propylhydrazine hydrochloride is approximately twice as active as the racemate and four times as active as the L-isomer when screened in vitro as an inhibitor of monoamine oxidase of mouse brain. In an antireserpine test in mice,5 the racemate appeared to be of the same order of activity as the D-isomer, which was approximately four times as active as the L-isomer. In normal mice, not reserpine treated, the racemate appeared to resemble closely the D-isomer in that both produced hyperactivity and hyperirritability during the first hour after treatment, a period of relative quiescency during the next hour, and then a second period of hyperactivity which lasted for several hours. The L-isomer, however, in normal mice manifested much less early hyperactivity although the delayed hyperactivity was observed.

(4) W. Leithe, Ber., **65B**, 660 (1932), reported a m.p. of 159–160°, $[\alpha]^{11}D+72^{\circ}$ (c, 1.14 in methanol).

(5) Drug administered to mice intraperitoneally four hours prior to the intraperitoneal administration of 10 mg./kg. of reserpine.

THE SQUIBB INSTITUTE FOR MEDICAL RESEARCH NEW BRUNSWICK, N. J. JACK BERNSTEIN KATHRYN A. LOSEE CHARLES I. SMITH BERNARD RUBIN

RECEIVED JULY 8, 1959

THE STRUCTURE OF ULEINE

Sir:

The alkaloid uleine, C₁₈H₂₂N₂, from Aspidosperma ulei Mgf., is remarkable for its C₁₇ skeleton which contains two carbons less than most other indole alkaloids.1 A previous investigation1 led to the tentative proposal of structure I which we now wish to replace by II. The infrared spectrum of the alkaloid exhibited bands at 877, 1635 and 3030 cm.-1 whilet he n.m.r. spectrum (all values for 60 mc. in CDCl₃) possessed peaks at 68, 86 (2 vinyl H); -134 (NH of indole); -73 to -38 c.p.s. (4 arom. H) relative to the benzene proton at 0 c.p.s. These findings, coupled with earlier ultraviolet evidence,1 demand part structure III. In agreement with III the bands associated with the terminal methylene group were missing in the spectra of dihydrouleine. The optically inactive IV, available by two Hofmann degradations, is a vinylcarbazole. Thus, osmylation of IV gave a diol which on cleavage with periodate was converted to formaldehyde and the yellow aldehyde

(1) J. Schmutz, F. Hunziker and R. Hirt, Helv. Chim. Acta, 40, 1189 (1957); 41, 288 (1958).

⁽¹⁾ J. H. Biel, A. E. Drukker, T. F. Mitchell, E. P. Sprengeler, P. A. Nuher, A. C. Conway and A. Horita, This Journal, 81, 2805 (1959).

^{(2) &}quot;Amine Oxidase Inhibitors," Ann. N. Y. Acad. Sci., in press.
(3) H. L. Yale, K. Losee, J. Martins, M. Holsing, F. M. Perry and J. Bernstein, This Journal, 75, 1933 (1953).